Deutsche Bank’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-452,119
| Closed | -$836K | – | 4072 |
|
|
2023
Q1 | $836K | Buy |
452,119
+7,399
| +2% | +$9.16K | ﹤0.01% | 2207 |
|
|
2022
Q4 | $494K | Sell |
444,720
-62,686
| -12% | -$89.2K | ﹤0.01% | 2453 |
|
|
2022
Q3 | $1.19M | Buy |
507,406
+421,671
| +492% | +$1.49M | ﹤0.01% | 1870 |
|
|
2022
Q2 | $260K | Buy |
85,735
+4,878
| +6% | +$23.7K | ﹤0.01% | 3015 |
|
|
2022
Q1 | $549K | Buy |
80,857
+30,265
| +60% | +$216K | ﹤0.01% | 2693 |
|
|
2021
Q4 | $422K | Buy |
50,592
+31,635
| +167% | +$261K | ﹤0.01% | 2942 |
|
|
2021
Q3 | $141K | Sell |
18,957
-614
| -3% | -$3.8K | ﹤0.01% | 3743 |
|
|
2021
Q2 | $133K | Buy |
19,571
+8,355
| +74% | +$69.4K | ﹤0.01% | 4015 |
|
|
2021
Q1 | $115K | Sell |
11,216
-1,041
| -8% | -$11.4K | ﹤0.01% | 3906 |
|
|
2020
Q4 | $86K | Buy |
12,257
+3,475
| +40% | +$27K | ﹤0.01% | 3929 |
|
|
2020
Q3 | $72K | Buy |
8,782
+839
| +11% | +$5.2K | ﹤0.01% | 3706 |
|
|
2020
Q2 | $55K | Buy |
7,943
+1,252
| +19% | +$6.75K | ﹤0.01% | 3773 |
|
|
2020
Q1 | $32K | Sell |
6,691
-33,379
| -83% | -$192K | ﹤0.01% | 3750 |
|
|
2019
Q4 | $348K | Sell |
40,070
-43,492
| -52% | -$235K | ﹤0.01% | 2914 |
|
|
2019
Q3 | $277K | Sell |
83,562
-31,589
| -27% | -$126K | ﹤0.01% | 2991 |
|
|
2019
Q2 | $569K | Sell |
115,151
-47,701
| -29% | -$253K | ﹤0.01% | 3194 |
|
|
2019
Q1 | $1.01M | Buy |
162,852
+12,557
| +8% | +$60.7K | ﹤0.01% | 2985 |
|
|
2018
Q4 | $506K | Buy |
150,295
+40,282
| +37% | +$188K | ﹤0.01% | 3317 |
|
|
2018
Q3 | $716K | Buy |
110,013
+65,860
| +149% | +$490K | ﹤0.01% | 3557 |
|
|
2018
Q2 | $339K | Buy |
44,153
+17,917
| +68% | +$258K | ﹤0.01% | 4041 |
|
|
2018
Q1 | $585K | Sell |
26,236
-6,440
| -20% | -$143K | ﹤0.01% | 3617 |
|
|
2017
Q4 | $416K | Buy |
32,676
+11,805
| +57% | +$174K | ﹤0.01% | 3702 |
|
|
2017
Q3 | $323K | Buy |
20,871
+7,233
| +53% | +$102K | ﹤0.01% | 3631 |
|
|
2017
Q2 | $189K | Buy |
13,638
+5,542
| +68% | +$119K | ﹤0.01% | 3952 |
|
|
2017
Q1 | $177K | Buy |
+8,096
| New | +$172K | ﹤0.01% | 3656 |
|
Other funds holding JNCE
Deutsche Bank's JNCE Position: Q2 2023 in Review
Deutsche Bank sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 452,119 shares — an estimated $836K sold.
Deutsche Bank first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $1.19M in Q3 2022. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Deutsche Bank reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Deutsche Bank sold 452,119 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $836K.
- Deutsche Bank first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Deutsche Bank's Jounce Therapeutics, Inc. Common Stock position peaked at $1.19M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Deutsche Bank's 13F filing for Q2 2023, filed 14 Aug 2023.